Tin tức & Cập nhật
Lọc theo Chuyên ngành:

Abemaciclib plus NSAI improves survival in advanced breast cancer
Combination treatment with abemaciclib and a nonsteroidal aromatase inhibitor (NSAI) as initial therapy, compared with NSAI alone, helps extend survival in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer, results of the MONARCH 3 study have shown.
Abemaciclib plus NSAI improves survival in advanced breast cancer
25 Aug 2024
Standardized guidelines missing for treatment of GILCNEC
Patients with gastrointestinal large cell neuroendocrine carcinoma (GILCNEC) show varying prognosis depending on the site of the primary tumour, suggests a study. Unfortunately, there remains no standardized consensus guidelines to manage GILCNEC.
Standardized guidelines missing for treatment of GILCNEC
23 Aug 2024
Neoadjuvant regorafenib, nivolumab, SCRT combination looks good for rectal cancer
Treatment with the combination of regorafenib, nivolumab, and short-course radiotherapy (SCRT) in the neoadjuvant setting has induced response in stage II-III rectal adenocarcinoma in the phase II REGINA trial, meeting the predefined statistical criteria.
Neoadjuvant regorafenib, nivolumab, SCRT combination looks good for rectal cancer
22 Aug 2024
Cervical cancer: PFS advantage with pembrolizumab plus CCRT consistent in Asians
Patients with high-risk locally advanced cervical cancer in East Asia get progression-free survival (PFS) boost with pembrolizumab plus concurrent chemoradiotherapy (CCRT), similar to those observed in the overall population of the phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study.
Cervical cancer: PFS advantage with pembrolizumab plus CCRT consistent in Asians
21 Aug 2024
Jaundice, fluid retention in HCC tied to shorter survival
The presence of jaundice or fluid retention among patients with hepatocellular carcinoma (HCC) is associated with a shorter overall survival (OS), suggests a Singapore study.